Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals Inc. (AGN) receives positive feedback from the U.S. FDA for its research on Ifenprodil to treat chronic cough
  • In Algernon’s pre-clinical animal cough study, Ifenprodil shows both a dramatic reduction in cough count and a delay in cough onset
  • Ifenprodil shows a statistically significant delay in the onset of the first cough
  • Ifenprodil has no known taste disturbance
  • Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent and is trading at $8.41 per share as of 11:08 p.m. EST

Algernon Pharmaceuticals Inc. (AGN) has received positive feedback from the U.S. FDA for its research on Ifenprodil to treat chronic cough. 

Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).

The meeting with U.S. FDA provided guidance on the Phase 2b protocol design that was submitted by Algernon.

The U.S. FDA requested standard testing must be completed prior to beginning the Phase 2b study.

Algernon estimates the testing will take approximately 90 days to complete.

In Algernon’s pre-clinical animal cough study, Ifenprodil shows both a dramatic reduction in cough count and a delay in cough onset.

Algernon also reports positive trending data from the chronic cough part of its Phase 2 idiopathic pulmonary fibrosis and chronic cough study.

The analysis examined 24-hour and waking cough counts.

Gefapixant, another trial drug for chronic cough, was also tested in the study.

Pharmidex, conducted the in-vivo cough study.

Data from this study demonstrates that at clinically relevant doses:

  • Ifenprodil shows a reduction of 42 per cent in mean cough frequency vs. untreated control.
  • Gefapixant shows a 20 per cent reduction in mean cough frequency vs. untreated control.

Ifenprodil shows a statistically significant delay in the onset of the first cough.

Gefapixant also shows a reduction in cough onset, but the difference was not significant.

Ifenprodil has no known taste disturbance.

Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent and is trading at $8.41 per share as of 11:08 p.m. EST.

More From The Market Herald

" Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Medicenna Therapeutics Corp. (MDNA) announced the publication of preclinical data on MDNA11.

" Clearmind Medicine (CSE:CMND) engages the Independent Trading Group as a market maker and Thunder11 as a PR agency

Clearmind Medicine Inc. (CMND) has engaged the services of Independent Trading Group to provide market-making services.

" Psyched Wellness (CSE:PSYC) provides update on study with the National Research Council of Canada

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).
codikoat, covid protection

" PharmaDrug (CSE:PHRX) begins manufacturing PD-001 for treatment of rare cancers and COVID-19

PharmaDrug (PHRX) has begun manufacturing PD-001, its oral formulation of cepharanthine, for cancer and infectious disease studies.